Skip to main content
Premium Trial:

Request an Annual Quote

Definiens, Merck KGaA Partner for Biomarker Discovery

NEW YORK (GenomeWeb) — Definiens said today that it has entered a biomarker alliance with Germany's Merck KGaA.

Under the terms of the multi-year deal, Merck's healthcare business will use Definiens' web-based collaboration software platform — which enables the uploading, accessing, searching, and sharing of data — to support its use of Definiens' Tissue Phenomics image-analysis technologies for biomarker quantification including immuno-profiling.

Additional terms were not disclosed.

"This partnership agreement is a testament to Definiens' ability to transform tissue image data into valuable insights using our proprietary data mining methods for biomarker discovery," Oliver Lehner, vice president of business development and partnering at Definiens, said in a statement.

Last year, Definiens — a subsidiary of AstraZeneca — expanded its cancer biomarker alliance with NeoGenomics to include assay development and automation. In late 2016, Takeda began using Definiens' cloud-based digital pathology platform in its translational and biomarker research.